Noun
efalizumab (uncountable)
(pharmacology) A recombinant humanized monoclonal antibody, formerly available to treat autoimmune diseases, especially psoriasis, by binding CD11a of lymphocyte function-associated antigen 1, and associated with fatal brain infections.